関連ニュース

Solventum trades at a significant discount to medical technology peers, with a forward P/E of 13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a pot

Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff

Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue gr